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Dear Sir,
Several case control studies and a recent prospective study showed
that in patients with (idiopathic) venous thrombosis mild hyperho-
mocysteinemia (HH) can be observed 2-3 times more frequently than in
controls (1-3). The pathogenetic explanation for this clinical observa-
tion is not known. In principal a thrombotic tendency can originate in
the blood, in the vessel wall or at the level of thrombocytes. The ques-
tion that we wanted to answer was whether the thrombotic tendency
that might accompany HH is caused by a higher capacity of these per-
sons to generate thrombin. The plasmatic component of a thrombotic
tendency might be reflected in the capacity of the platelet poor plas-
ma to generate thrombin. This capacity can be assessed by measuring
the endogenous thrombin potential (ETP), i.e. the surface under the
thrombin generation curve (4-6). It has been shown that the ETP is 
significantly increased in such plasma based thrombotic tendencies as
deficiencies in AT and mutated Factor V Leiden (6,7). The influence of
exogenous activated protein C (APC) (8, 9) and exogenous thrombo-
modulin (TM) (10, 11) on the inhibition of the ETP was recently shown
and was used to screen for a deficient protein C pathway. In order to see
whether a plasmatic component can explain the thrombotic tendency in
HH, we tested the possible relationship between the concentration of
homocysteine (tHcy) and thrombin generation in a group of healthy
controls, without any venous thrombotic events in the past. Blood 
samples of 30 persons with elevated levels of tHcy (> 18 mmol/l; mean:
22.7 mmol/l) were selected. Samples of 30 persons matched for age and
sex with normal tHcy levels (mean: 14.2 mmol/l) were used as controls
(for details on study group selection see ref. 12). Homocysteine values
of >18 mmol/l are clearly associated with increased risk for venous
thrombosis (13, 14). We deliberately did not include patients with 
venous thrombosis in the past, so as to exclude the possibility of 
plasma changes caused by the thrombotic process itself. 
We determined the ETP under standard conditions (extrinsically and
intrinsically) and in the presence of exogenous APC or TM. The assay
method for determining the ETP is based on the continuous monitoring
of thrombin formation using a slow reacting thrombin substrate 
essentially as described earlier (4) which method has been adapted for
high throughput screening on a Cobas centrifugal analyzer (6). The
anticoagulant response towards TM was expressed as the thrombo-
modulin ratio (TMR); TMR: (ETP+TM/ETP-TM)pool / (ETP+TM/
ETP
-TM)sample. The anticoagulant response towards APC was expressed
as the APC sensitivity ratio (APC-sr): (a2M–IIa+APC/a2M–IIa-APC)sample /
(a2M–IIa+APC/a2M–IIa-APC)pool.
The data on the subjects under study are given in Table 1. There was
a narrow association between the intrinsic and extrinsic ETP. The 
Pearson correlation is 0.876 (p = 0.001) (data not shown). However, for
both intrinsic ETP and extrinsic ETP we found no correlation with
tHcy. Comparing the two different groups no difference was present
between those with normal tHcy levels and those with elevated tHcy
levels. The intrinsic ETP in those with elevated tHcy was 412 (99% of
reference plasma) similar to those with normal tHcy. The extrinsic ETP
was 100% of reference plasma in those with eleveated tHcy and 106%
of reference plasma in those with normal tHcy. There was clearly no as-
sociation between tHcy and TMR (coefficient is 0.04; p = 0.74) and no
difference between the group with high tHcy and those with normal
tHcy was observed. Also no difference in APC-sr ratio could be 
observed between those with high and normal tHcy levels.
Since no association of the ETP and homocysteine levels was 
observed and no influence of homocysteine on the ETP in the presence
of APC or TM, our data do not support the idea that HH acts via the
plasmatic coagulation system. Others suggested a role for factor V or
activated protein C. In addition an enhanced turnover or diminished
formation of thrombomodulin has been suggested though not 
supported by all studies (reviewed in 1 and 15). It should be realized
however that most of the observations were made in in vitro systems
and that in the in vitro experiments very high levels of (free) homo-
cysteine – up to 10 mmol/l – were used. These values differ far from the
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in vivo situation and it is questionable in our opinion whether these in
vitro experiments represent the clinical situation. Not finding an 
association between mild HH and the ETP renders a direct influence of
HH on plasmatic thrombin generation improbable. Therefore other 
factors might be relevant such as the fibrinolytic pathway, enhanced 
tissue factor activity, enhanced platelet aggregation, increased platelet
adhesion on endothelial cells, abnormal nitrogen oxides, abnormal 
endothelium-derived relaxing factor and inhibition of von Willebrand
factor production (1, 15). Most of the studies supporting these hypo-
theses are however again limited by the high levels of homocysteine
used in the in vitro experiments. It has also been shown that homocys-
teine might induce altered gene expression in endothelial cells, genes
that might possibly be related to the process of thrombosis (16, 17). 
Until now – to our knowledge – there is however no clear parameter
observed in man that might be a clue for the pathogenetic process 
involved in the association of mild HH and venous thrombosis. We feel
such a parameter is urgently needed to proof that the epidemiological
association between HH and venous thrombosis can more likely be
interpreteted as a causative one. Furthermore such a parameter would
be very helpful in treatment strategies for HH. Vitamins (folic acid) 
can easily correct HH but any antithrombotic effect of any treatment
cannot be claimed yet (12, 15, 18).
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